Semaglutide: the benefits people report, the side effects they live with, and who has a reason to be careful.

The short version

Here is the honest picture of semaglutide effects. The benefit people describe most is that hunger gets quiet — they feel full sooner, eat less, and stop thinking about food all day. Most people lose weight, and people with diabetes often see better blood-sugar numbers. The trade-off is the stomach: nausea is common, especially in the first weeks and after each dose increase, and some people get foul "sulfur" burps, constipation or diarrhea, tiredness, or headaches. A smaller group notices hair shedding or a more hollow face — usually from losing weight fast, not the drug itself. Below, the community reports come first (clearly labeled as anecdote), then the cited safety cautions from the actual studies, including who should be careful and why.

What people report

These are effects reported by people using semaglutide and gathered from patient-review communities — anecdotal, not clinical evidence, and not verified by controlled trials. No doses are attached, and a single person's experience is not a finding.

Benefits people describe

• Appetite suppression / quieter "food noise" (frequently reported). By far the most common benefit is that the constant background chatter about food goes quiet, often within the first week or two. People say they feel full faster, eat a third to a half of their old portions, and stop obsessing over the next meal. Many call this the single most life-changing effect.
• Reduced cravings for sugar, sweets and greasy food (frequently reported). People repeatedly say sweet-tooth and sugar cravings drop sharply, and that fried, greasy, high-fat foods stop appealing — sometimes turning slightly off-putting. Several describe naturally drifting toward fruit, vegetables and lighter meals.
• Weight loss (frequently reported). The overwhelming majority report losing weight, often describing it as steady and substantial over several months, with the pace slowing after the early stretch. Many tie it directly to eating much less.
• Better blood-sugar control (commonly reported). Among people using it for type 2 diabetes, a common theme is markedly improved blood-sugar and A1C readings, with some morning and long-term averages dropping into normal ranges.
• Reduced desire to drink alcohol (occasionally reported). A recurring secondary observation is that the urge to drink fades along with food cravings, with some people simply losing interest.

Adverse effects people describe

• Nausea, sometimes with vomiting (frequently reported). Nausea is the single most reported side effect — roughly a third of reviewers — and a subset escalates to vomiting at its worst. It tends to peak in the first weeks and after each dose increase, often easing within a week or two, and flares after overeating or fatty food. Many manage it with smaller, lighter meals and plenty of water.
• Sulfur or "egg" burps (commonly reported). A distinctive complaint is foul-smelling burps people compare to rotten eggs or sulfur, often after a dose increase, sometimes with bloating and a sense of food sitting too long. Many describe them as embarrassing; some find they fade with time.
• Bowel changes — constipation and diarrhea (commonly reported). People report both extremes, sometimes alternating: very hard, infrequent stools, or diarrhea that is worse in the days right after a dose or after rich food.
• Acid reflux and heartburn (occasionally reported), often alongside burping and bloating, tracking with dose increases.
• Fatigue early on (commonly reported), especially the day or two after each injection and during the early weeks, usually easing with time.
• Food aversions, taste changes and over-suppressed appetite (occasionally reported) — active aversions to fatty or meaty food, a metallic taste, heightened smell sensitivity, and for a few, so little appetite they have to remind themselves to eat.
• Headaches and dizziness (occasionally reported), often linked to not drinking or eating enough; many say hydration helps.
• Injection-site reactions (sometimes reported) — minor, short-lived redness, itching or a small bump.

Semaglutide hair loss: what people report

Semaglutide hair loss is a real but smaller theme in patient reports — anecdotal, not clinical evidence. A subset of people describe increased hair shedding, usually noticed a few months in, alongside a thinner, more hollow or gaunt face with sunken temples and looser skin. Both are widely attributed to losing weight quickly rather than to the medication itself, and people generally describe the shedding as temporary. The cited evidence behind this — and why "telogen effluvium" is the leading explanation — is in the safety section below ^[18][19].

Safety & cautions

This is where the genuinely useful context lives — drawn from the trial and pharmacovigilance record, and cited. None of it is dosing advice.

Gastrointestinal intolerance, especially during dose escalation. Nausea, vomiting, diarrhea and constipation are the dominant adverse effects in trials and the leading reason people stop. In a pooled analysis of the STEP weight-management program these events were mostly mild-to-moderate and transient, concentrated around the titration period ^[13], and a dedicated safety review reported nausea in roughly one-third of patients ^[5]; real-world reporting is likewise dominated by gastrointestinal events ^[15]. This is clinical, not theoretical — the slowing of stomach emptying that causes it is part of how the drug works.

A boxed warning for medullary thyroid carcinoma (MTC). GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors derived from rodent studies, where tumors occurred at very high exposures. A dedicated assessment concluded that human data do not establish a clear increase in thyroid cancer attributable to semaglutide — so the signal is best framed as unconfirmed in humans — yet a personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN-2) is treated as a contraindication on the strength of the rodent finding ^[14][5].

Acute pancreatitis (a class warning). Pancreatitis is a recognized class warning, and treatment is conventionally stopped if it is suspected. The same safety review notes pancreatic-cancer signals remain ones for which firm conclusions cannot yet be drawn owing to low incidence — a precautionary caution, not a demonstrated risk increase ^[5].

Gallbladder and biliary disease. A dedicated safety review found an increased risk of gallstones (cholelithiasis), attributed largely to the rate and size of weight loss rather than direct drug toxicity — but the increase versus placebo is a real finding, not just theoretical ^[5].

Pre-existing diabetic retinopathy with rapid glucose correction. In SUSTAIN-6, diabetic-retinopathy complications were significantly more frequent with semaglutide (HR 1.76; 95% CI 1.11-2.78), concentrated among people with pre-existing retinopathy whose blood sugar was lowered quickly ^[2][5]. The leading interpretation is early worsening driven by the speed of correction rather than retinal toxicity; monitoring is advised when glucose is corrected fast. This is a trial signal in people with diabetes.

Loss of lean (muscle) mass. A STEP-program body-composition substudy found the weight lost included both fat and a meaningful share of lean mass ^[16]. Because rapid, large weight loss can erode muscle, this raises a sarcopenia concern (especially in older adults) and has driven research into protein intake and resistance training. The lean-mass loss is an observed finding; the downstream muscle-loss risk is a reasoned extrapolation.

Weight regain after stopping. In the STEP 1 extension, people regained a mean of about 11.6 percentage points of body weight within a year of stopping, and cardiometabolic gains reverted toward baseline ^[17]. This frames obesity treatment as ongoing rather than curative.

Hair shedding (telogen effluvium) with rapid weight loss. A pharmacovigilance analysis flagged an alopecia reporting signal for semaglutide and tirzepatide ^[18], and a separate dermatology study linked telogen effluvium — a reversible, diffuse shedding — to the size and speed of weight loss ^[19]. The signal is most consistent with rapid-weight-loss-driven shedding, not direct drug toxicity.

Pregnancy: contraindicated, with a long washout. Semaglutide is contraindicated in pregnancy per the label. Because its half-life is about a week, with full clearance only around five weeks after the last dose, guidance advises stopping well before a planned pregnancy (commonly cited as roughly two months) ^[11].

The oral form needs a strict empty stomach. Oral semaglutide is paired with an absorption enhancer (SNAC) and has very low oral absorption (~0.4-1%), so it must be taken on an empty stomach with only a little water, away from other food, drink and medicine — administration errors can sharply cut how much is absorbed ^[20][11].

Narrow-margin oral drugs during titration. A systematic review found GLP-1 receptor agonists generally do not cause clinically significant drug interactions despite slowed stomach emptying, but advised caution and monitoring for narrow-therapeutic-index oral drugs, especially during dose increases ^[21].

Semaglutide side effects: the trial-record summary

Pulling the cited record together, the semaglutide side effects that dominate the evidence are gastrointestinal and largely transient: nausea (about one-third of patients), vomiting, diarrhea and constipation, peaking during titration ^[13][5]. Increased gallstone risk is documented and tied to fast weight loss ^[5]. Diabetic-retinopathy worsening appeared in SUSTAIN-6 with rapid glucose correction ^[2]. Class warnings (thyroid C-cell tumors, pancreatitis) carry forward as contraindications and precautions without a confirmed human signal ^[14][5]. None of these is a reason to self-adjust anything — they are the map clinicians use, summarized here.

Compounded semaglutide: the regulatory context

Compounded semaglutide is the drug prepared by a compounding pharmacy rather than the approved manufactured product. During a federally declared shortage from roughly 2022 into early 2025, compounding pharmacies were permitted to produce it; once the shortage was declared resolved in 2025, those pathways were curtailed ^[12]. The approved-product evidence summarized across this site does not extend to compounded or non-pharmaceutical sources, which fall outside that trial base. This is regulatory context, not a recommendation about any product.

Then and now

Semaglutide is the product of decades of incretin-peptide chemistry, engineered for once-weekly dosing through resistance to the enzyme DPP-4 and tight, reversible binding to the blood protein albumin. It first reached FDA approval for type 2 diabetes in 2017, with an oral once-daily form following in 2019-2020 and a chronic weight-management indication in 2021 ^[1]. Its cardiovascular-outcomes evidence (SELECT) read out in 2023 ^[3] and its kidney-outcomes evidence (FLOW) in 2024 ^[6], with the matching heart and kidney indications approved in 2024-2025 and a fatty-liver (MASH) indication added in 2025 ^[12]. Unlike many compounds summarized in this kind of digest, semaglutide has never been an unapproved research chemical — its entire history is as a developed, trial-tested, regulator-reviewed medicine.